A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms

35 authors, including; Qiujin Shen; Yahui Feng; Xiaowen Gong; Yujiao Jia; Qingyan Gao; Xiaokang Jiao; Saibing Qi; Xueou Liu; Hui Wei; Jun Yan; Jianxiang Wang; Zhijian Xiao; Junren Chen

doi:10.1158/2767-9764.CRC-21-0194

A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms

35 authors, including, Qiujin Shen (Co-first Author), Yahui Feng (Co-first Author), Xiaowen Gong (Co-first Author), Yujiao Jia (Co-first Author), Qingyan Gao (Co-first Author), Xiaokang Jiao (Co-first Author), Saibing Qi (Co-first Author), Xueou Liu (Co-first Author), Hui Wei (Co-first Author), Jun Yan, Jianxiang Wang^*, Zhijian Xiao^*, Junren Chen^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

1 Downloads (CityUHK Scholars)

Abstract

Although the concept of “myeloid neoplasm continuum” has long been proposed, few comparative genomics studies directly tested this hypothesis. Here we report a multi-modal data analysis of 730 consecutive newly diagnosed patients with primary myeloid neoplasm, along with 462 lymphoid neoplasm cases serving as the outgroup. Our study identified a “Pan-Myeloid Axis” along which patients, genes, and phenotypic features were all aligned in sequential order. Utilizing relational information of gene mutations along the Pan-Myeloid Axis improved prognostic accuracy for complete remission and overall survival in adult patients of de novo acute myeloid leukemia and for complete remission in adult patients of myelodysplastic syndromes with excess blasts. We submit that better understanding of the myeloid neoplasm continuum might shed light on how treatment should be tailored to individual diseases. Significance: The current criteria for disease diagnosis treat myeloid neoplasms as a group of distinct, separate diseases. This work provides genomics evidence for a “myeloid neoplasm continuum” and suggests that boundaries between myeloid neoplastic diseases are much more blurred than previously thought. © 2022 The Authors; Published by the American Association for Cancer Research.

Original language	English
Pages (from-to)	258-276
Number of pages	19
Journal	Cancer Research Communications
Volume	2
Issue number	4
Online published	26 Apr 2022
DOIs	https://doi.org/10.1158/2767-9764.CRC-21-0194
Publication status	Published - Apr 2022
Externally published	Yes

Funding

This work was supported in part by the Tianjin Science and Technology Plan grant 20ZYJDSY00010 (to J. Wang), the Chinese Academy of Medical Sciences Initiative Fund for Medical Sciences grant 2020-I2M-C&T-A-020 (to Z. Xiao), and the State Key Laboratory of Experimental Hematology grant Z20–01 (to J. Chen). Y. Hu assisted in proofreading of the manuscript. The authors would like to express special thanks to T. Cheng for sponsoring the publication of this work through the “National Multidisciplinary Collaborative Diagnosis and Treatment Capacity Building Project for Major Diseases”.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher's Copyright Statement

This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

Access Output

10.1158/2767-9764.CRC-21-0194

335465306.pdfFinal Published version, 5.44 MBLicence: CC BY

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{c2cf3b0dceb34dc18782ac1d87ff1ef9,

title = "A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms",

abstract = "Although the concept of “myeloid neoplasm continuum” has long been proposed, few comparative genomics studies directly tested this hypothesis. Here we report a multi-modal data analysis of 730 consecutive newly diagnosed patients with primary myeloid neoplasm, along with 462 lymphoid neoplasm cases serving as the outgroup. Our study identified a “Pan-Myeloid Axis” along which patients, genes, and phenotypic features were all aligned in sequential order. Utilizing relational information of gene mutations along the Pan-Myeloid Axis improved prognostic accuracy for complete remission and overall survival in adult patients of de novo acute myeloid leukemia and for complete remission in adult patients of myelodysplastic syndromes with excess blasts. We submit that better understanding of the myeloid neoplasm continuum might shed light on how treatment should be tailored to individual diseases. Significance: The current criteria for disease diagnosis treat myeloid neoplasms as a group of distinct, separate diseases. This work provides genomics evidence for a “myeloid neoplasm continuum” and suggests that boundaries between myeloid neoplastic diseases are much more blurred than previously thought. {\textcopyright} 2022 The Authors; Published by the American Association for Cancer Research.",

author = "{35 authors, including} and Qiujin Shen and Yahui Feng and Xiaowen Gong and Yujiao Jia and Qingyan Gao and Xiaokang Jiao and Saibing Qi and Xueou Liu and Hui Wei and Bingqing Huang and Ningning Zhao and Xiaoqiang Song and Yueshen Ma and Shihao Liang and Donglei Zhang and Li Qin and Ying Wang and Shiqiang Qu and Yao Zou and Yumei Chen and Ye Guo and Shuhua Yi and Gang An and Zengtao Jiao and Song Zhang and Linfeng Li and Jun Yan and Huijun Wang and Zhen Song and Yingchang Mi and Lugui Qiu and Xiaofan Zhu and Jianxiang Wang and Zhijian Xiao and Junren Chen",

year = "2022",

month = apr,

doi = "10.1158/2767-9764.CRC-21-0194",

language = "English",

volume = "2",

pages = "258--276",

journal = "Cancer Research Communications",

issn = "2767-9764",

publisher = "American Association for Cancer Research",

number = "4",

}

A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms. / 35 authors, including; Shen, Qiujin (Co-first Author); Feng, Yahui (Co-first Author) et al.
In: Cancer Research Communications, Vol. 2, No. 4, 04.2022, p. 258-276.

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

TY - JOUR

T1 - A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms

AU - 35 authors, including

AU - Shen, Qiujin

AU - Feng, Yahui

AU - Gong, Xiaowen

AU - Jia, Yujiao

AU - Gao, Qingyan

AU - Jiao, Xiaokang

AU - Qi, Saibing

AU - Liu, Xueou

AU - Wei, Hui

AU - Huang, Bingqing

AU - Zhao, Ningning

AU - Song, Xiaoqiang

AU - Ma, Yueshen

AU - Liang, Shihao

AU - Zhang, Donglei

AU - Qin, Li

AU - Wang, Ying

AU - Qu, Shiqiang

AU - Zou, Yao

AU - Chen, Yumei

AU - Guo, Ye

AU - Yi, Shuhua

AU - An, Gang

AU - Jiao, Zengtao

AU - Zhang, Song

AU - Li, Linfeng

AU - Yan, Jun

AU - Wang, Huijun

AU - Song, Zhen

AU - Mi, Yingchang

AU - Qiu, Lugui

AU - Zhu, Xiaofan

AU - Wang, Jianxiang

AU - Xiao, Zhijian

AU - Chen, Junren

PY - 2022/4

Y1 - 2022/4

N2 - Although the concept of “myeloid neoplasm continuum” has long been proposed, few comparative genomics studies directly tested this hypothesis. Here we report a multi-modal data analysis of 730 consecutive newly diagnosed patients with primary myeloid neoplasm, along with 462 lymphoid neoplasm cases serving as the outgroup. Our study identified a “Pan-Myeloid Axis” along which patients, genes, and phenotypic features were all aligned in sequential order. Utilizing relational information of gene mutations along the Pan-Myeloid Axis improved prognostic accuracy for complete remission and overall survival in adult patients of de novo acute myeloid leukemia and for complete remission in adult patients of myelodysplastic syndromes with excess blasts. We submit that better understanding of the myeloid neoplasm continuum might shed light on how treatment should be tailored to individual diseases. Significance: The current criteria for disease diagnosis treat myeloid neoplasms as a group of distinct, separate diseases. This work provides genomics evidence for a “myeloid neoplasm continuum” and suggests that boundaries between myeloid neoplastic diseases are much more blurred than previously thought. © 2022 The Authors; Published by the American Association for Cancer Research.

AB - Although the concept of “myeloid neoplasm continuum” has long been proposed, few comparative genomics studies directly tested this hypothesis. Here we report a multi-modal data analysis of 730 consecutive newly diagnosed patients with primary myeloid neoplasm, along with 462 lymphoid neoplasm cases serving as the outgroup. Our study identified a “Pan-Myeloid Axis” along which patients, genes, and phenotypic features were all aligned in sequential order. Utilizing relational information of gene mutations along the Pan-Myeloid Axis improved prognostic accuracy for complete remission and overall survival in adult patients of de novo acute myeloid leukemia and for complete remission in adult patients of myelodysplastic syndromes with excess blasts. We submit that better understanding of the myeloid neoplasm continuum might shed light on how treatment should be tailored to individual diseases. Significance: The current criteria for disease diagnosis treat myeloid neoplasms as a group of distinct, separate diseases. This work provides genomics evidence for a “myeloid neoplasm continuum” and suggests that boundaries between myeloid neoplastic diseases are much more blurred than previously thought. © 2022 The Authors; Published by the American Association for Cancer Research.

UR - http://www.scopus.com/inward/record.url?scp=85194932474&partnerID=8YFLogxK

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85194932474&origin=recordpage

U2 - 10.1158/2767-9764.CRC-21-0194

DO - 10.1158/2767-9764.CRC-21-0194

M3 - RGC 21 - Publication in refereed journal

C2 - 36873623

SN - 2767-9764

VL - 2

SP - 258

EP - 276

JO - Cancer Research Communications

JF - Cancer Research Communications

IS - 4

ER -

A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms

Abstract

Funding

UN SDGs

Publisher's Copyright Statement

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this